The mid-stage study of INCB013739 demonstrated that treatment of type 2 diabetes mellitus patients with INCB013739 for 28 days significantly improved hepatic and peripheral insulin sensitivity and reduced fasting plasma glucose, plasma low density lipoprotein and total cholesterol levels.22,23. Here, INS is linked to type 2 diabetes mellitus.